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Abstract
Background: As the most common invasive fungal infection, invasive aspergillosis (IA) remains a serious
complication in immunocompromised patients, leading to increased mortality. Antifungal therapy is expensive and
may result in severe adverse effects.
The aim of this study was to determine the incidence of invasive aspergillosis (IA) cases in a tertiary care university
hospital using a standardized surveillance method.
Methods: All inpatients at our facility were screened for presence of the following parameters: positive
microbiological culture, pathologist’s diagnosis and antifungal treatment as reported by the hospital pharmacy.
Patients fulfilling one or more of these indicators were further reviewed and, if appropriate, classified according to
international consensus criteria (EORTC).
Results: 704 patients were positive for at least one of the indicators mentioned above. Applying the EORTC
criteria, 214 IA cases were detected, of which 56 were proven, 25 probable and 133 possible. 44 of the 81 (54%)
proven and probable cases were considered health-care associated. 37 of the proven/probable IA cases had
received solid organ transplantation, an additional 8 had undergone stem cell transplantation, and 10 patients
were suffering from some type of malignancy. All the other patients in this group were also suffering from severe
organic diseases, required long treatment and experienced several clinical complications. 7 of the 56 proven cases
would have been missed without autopsy. After the antimycotic prophylaxis regimen was altered, we noticed a
significant decrease (p = 0.0004) of IA during the investigation period (2003-2007).
Conclusion: Solid organ and stem cell transplantation remain important risk factors for IA, but several other types
of immunosuppression should also be kept in mind. Clinical diagnosis of IA may be difficult (in this study 13% of
all proven cases were diagnosed by autopsy only). Thus, we confirm the importance of IA surveillance in all high-
risk patients.
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Background
As the most common invasive fungal infection, invasive
aspergillosis (IA) remains a serious complication in
immunocompromised patients [1-3]. The number of
patients at risk is increasing due to new intensive che-
motherapy regimens and a growing number of stem cell
and solid organ recipients. Because Aspergillus spp.a r e
widely found in the environment, water, soil and in
decomposing plants, spores can be easily inhaled and
may then cause invasive pulmonary disease. The IA inci-
dence in organ transplant recipients may be as high as
5%; mortality rates of up to 80% have been reported [4].
Antifungal therapy is expensive and adverse effects can
be severe [5]. Thus, the Centers for Disease Control and
Prevention (CDC) recommend the need for surveillance
of pulmonary IA in hospitals [6].
Unfortunately, surveillance of IA is difficult to perform
and various methods exist aiming to detect cases of IA
using computerized data or chart review. Usually
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are required to correctly evaluate cases [7-9].
The aim of the five year surveillance study presented
here was to obtain an overview of IA cases in the entire
university hospital using a standardized surveillance
method.
Methods
Facility
The study was conducted at Hannover Medical School,
a1 , 4 1 9 - b e du n i v e r s i t yh o s p ital with 50,000 inpatient
admissions per year. A large proportion of the patients
are severely immunocompromised because Hannover
Medical School focuses on transplantation of solid
organs, stem cells and bone marrow. From 2003
through 2007, about 2,180 organ transplantations and
625 stem cell transplantations were performed. Intensive
care units (ICUs) and hematologic transplant units are
equipped with HEPA air filtration and have positive air
pressure (reverse isolation) rooms.
Construction works
Hannover Medical School was undergoing major con-
struction and renovations during the entire study period.
Work was also being carried out in patient care areas in
clinical buildings. ICUs and non-ICUs were affected in
equal measure. Units were only closed completely for
extensive construction work. In order to prevent spread
of Aspergillus spores, we introduced the following pre-
vention measures as recommended by the CDC: (a)
work sites were isolated with impermeable barriers, (b)
specific routes were defined for transportation of materi-
als, machines and building site workers, and (c) cleaning
of units was intensified.
Air sampling
At Hannover Medical School, air sampling is performed
routinely twice a year on ICU and hematologic-oncolo-
gic wards and was also performed throughout the dura-
tion of construction works.
Air sampling was undertaken with one of the most
frequently used air samplers, the Reuter centrifugal sam-
pler (RCS High flow Air Sampler 35318, Biotest Diag-
nostics Corporation, Denville, NJ, USA).
Surveillance method and case definition
The Department of Hospital Epidemiology and Infection
Control reviewed the following data and classified IA
cases as “proven”, “probable”,o r“possible” according to
European Organisation for Research and Treatment of
Cancer (EORTC) criteria [10,11].
T h ef i r s ta n dm o s ti m p o r t a n ts t e pi nt h es u r v e i l l a n c e
method employed here involved a microbiology database
query using the keyword Aspergillus to retrieve possible
cases of IA in microbiological samples.
Data of all patients were reviewed for the following
indicators:
(a) Microbiology: An electronic alert was sent by the
microbiological laboratory as soon as there were at least
two positive results: either a positive culture for Asper-
gillus spp. (detection of septated hyphae) or serum
found positive for Aspergillus antigen using the galacto-
mannan Platelia Aspergillus test with a cut-off of 0.5
(Bio-Rad). The positive results were documented in a
table via electronic retrieval, and then evaluated by our
infection control team.
(b) Pathology: Proof of mould infection in histological
samples or in autopsy. Electronic retrieval involved
searching for the keywords: mould, hyphae, mycosis,
invasive mycosis, invasive aspergillosis, aspergillus. Med-
ical reports including these keywords were evaluated by
our infection control team. (c) Antimycotics: Use of at
least one of the following substances was documented:
amphotericin B, caspofungin, voriconazole, and flucyto-
sine. The antimycotics are documented in an electronic
program operated by the in-house pharmacy. The charts
of all the patients who had received at least one of the
antymycotics were evaluated by our infection control
team. The reason for application (prophylaxis vs. ther-
apy) as well as the type of application (oral vs. intrave-
nous) was also recorded.
In addition: Radiological findings that raised suspicion
of mould infection (halo sign, air-crescent sign or other
signs suggestive of invasive sinusitis). Patients showing
one of the three symptoms were screened for radiologi-
cal signs using the keywords mould infection, aspergillo-
sis, invasive aspergillosis, fungal infection, halo sign,
crescent sign. Medical reports including these keywords
were later evaluated by our infection control team.
Most of these parameters were collected from the hos-
pital’s patient data documentation system. Only autopsy
reports had to be screened separately as they are not yet
available electronically in our system
We excluded cystic fibrosis patients who had not yet
undergone lung transplantation because they are often
colonized without invasive infection. Patients with inva-
sive candidiasis were also excluded. All other inpatients
were included in the study. A case of IA was classified
as being likely to have been nosocomially acquired if
clinical symptoms appeared more than seven days after
admission with at least one negative respiratory culture
before the positive index sample [7]. Cases with an
infection occurring within seven days of admission were
defined as possibly nosocomial.
C a s e sp o s i t i v ef o ro n eo rm o r eo ft h e s ei n d i c a t o r s
were then further evaluated using EORTC criteria
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personnel [10,11]. We collected demographic data (age,
gender), potential host factors that might predispose for
IA, and clinical, microbiological and histological
diagnoses.
Infection was defined as early if occurring within the
first 100 days of transplantation, and as late if detected
later than 100 days.
As the Department of Hospital Epidemiology and
Infection Control, we are entrusted with analysis of data
for surveillance purposes, ando b t a i n e df u l lp e r m i s s i o n
from our hospital’s administration to use of all the data
generated.
Statistical analysis
Monthly or annually incidence densities of nosocomial
IA/1000 patient days were calculated as the number of
patients with any IA event in a given month or year,
divided by the number of patient days for that month or
that year and multiplied by 1000.
Mortality refers to in-hospital mortality only, because
there was no post-discharge surveillance of patients and
no surveillance of outpatients.
Time trends of the five year surveillance programme
were investigated. Differences of annual incidence densi-
ties were calculated using exponential MLE-Test. p
values < 0.05 were considered statistically significant. To
s h o wu s eo fa n t i f u n g a lt h e r a p y ,w ec o l l e c t e da l ld a t ao n
antifungal therapy, calculated the daily defined dosages
(DDD) per year and correlated them with cases.
Results
Characteristics of all IA cases
During the study period, there were 234,095 admissions
to Hannover Medical School.
At least one of the pharmacological, pathological or
microbiological indicators (in addition clinical and radi-
ological signs) was reported in 704 patients. Only these
cases had do be reviewed in more detail. Of this num-
ber, 214 cases of IA were confirmed as either proven
(56; 26%), probable (25; 12%) or possible (133; 62%). 35
proven cases and 3 probable cases (overall 44% of all
proven and probable cases) were classified as health-
care associated. The number of indicators and the num-
ber of cases resulting are shown in table 1.
58 of the 214 IA cases died (crude mortality rate 27%).
Mortality rates differed depending on the classification
of cases: 25 of 56 proven cases (46%), 11 of 25 probable
cases (44%), and 22 of 133 possible cases (17%).
The incidence of nosocomial IA (proven and probable
cases) was 1.85% in organ transplanted patients (mostly
from cardiothoracic surgery ICUs) and 0.97% in stem
cell transplanted patients. We detected no Aspergillus
outbreaks, nor did we find any correlation between the
onset of IA and seasonal variation or construction
works. Incidence densities declined when comparing
data on invasive Aspergillosis from 2007 with those of
2003 (p = 0.0004). Changes in incidence densities
between the years are shown in table 2.
Hospital-acquired cases of IA
The air outlets of indoor air supply systems were
checked regularly for presence of mould spores. Further-
more, the concentration of particles, bacteria and fungi
was routinely measured inside and outside the building
with no increase being noted during this study. Inci-
dence rates of IA cases are shown in Figure 1 and 2.
Characteristics of the 81 proven and probable IA cases
The median age of proven and probable IA cases was 51
years (50 years on average, 25
th percentile: 34 years; 75
th
percentile: 63 years). There were 59 male and 32 female
cases (male/female ratio 2.5). Underlying diseases of the
proven and probable IA cases were (a) hematological
diseases (n = 26; 21%), (b) severe chronic diseases of the
lung (n = 30; 24%), (c) liver diseases (n = 20; 16%), (d)
solid tumors (n = 10; 12%), and (e) chronic renal dis-
eases (n = 7; 6%).
Detailed data on underlying diseases and distribution
of organ transplantations for IA cases are shown in
table 3 and 4.
39 patients (48%) had transplantations (35 organ
transplantations and 4 stem cell transplantations).
44 of the proven and probable cases (44/81) were
categorized as being of likely nosocomial origin, 19
cases (19/81) were possible nosocomial cases.
Table 1 Cases found through indicators and IA cases resulting (with each method)
all cases cases with one indicator cases with two indicators cases with three indicators
M* PA* M, PH* M, PA* PH, PA* M, PH, PA*
no IA 490 231 6 253 - - -
proven IA 56 3 6 17 13 2 15
probable IA 25 6 - 17 - 1 1
possible IA 133 45 - 88 - - -
* M = Microbiological indicator, PA = Pathological indicator, PH = Pharmacological indicator
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as early infection (up to 100 days after transplantation);
11 likely nosocomial cases (11/39) showed late infection
(detected > 100 days).
We identified 10 patients suffering from some kind of
malignant tumor and a further 26 patients with chronic
organ diseases. Detailed information on the underlying
diseases of these patients is given in table 4. All patients
suffering from chronic organic diseases had received
long term treatment, or had experienced severe compli-
cations (e.g. insufficiency of anastomoses, re-operations,
or peritonitis). However, they had neither undergone
transplantation, nor were they immunosuppressed..
The mortality rate for all proven and probable cases
was 45%. Seven of the 11 proven IA cases who had not
received prior antifungal therapy died (64%). 72 proven/
probable cases (89%) had been treated with immunosup-
pressive therapy prior to first signs of IA (e.g. high dose
steroidal therapy, cyclosporine, or chemotherapy). Most
of the cases were detected in review of microbiology
and pharmacy reports (58 cases, 72%). 34 cases (42%)
had positive pathology results.
Microbiological data
Of the 81 proven and probable cases, Aspergillus sp. was
identified in a clinical sample of 55 cases (68%). 34 cases
(57%) had positive pathological results. 16 proven IA
cases (29%) were detected by autopsy, seven of which
did not have any other advance symptoms, meaning
that 13% of all proven IA cases would have been missed
without subsequent autopsy. Among the 133 possible
cases, 49 had positive clinical samples (table 5).
Data on antifungal therapy
As shown in Figure 3, the antifungal therapy regimen
changed during the investigation period. Overall use of
antimycotics increased (from 32,705 DDD in 2003 to
36,327 DDD in 2007). However, use of flucytosine was ter-
minated in 2005. Instead, posaconazole was introduced in
2006, with consumption increasing by factor 7 in 2007
(from 131 to 998 DDD). Anidulafungin was introduced in
2007 (27 DDD). A reduction in use of amphotericin B
(from 7786 to 5164 DDD) and itraconazole (from 7,964 to
4,489 DDD) became apparent during the study, while use
of caspofungin (from 1,582 to 4,080 DDD) and voricona-
zole (from 2,141 to 5,311 DDD) increased.
During the investigation period, the departments of
hemato-oncology and cardio-thoracic surgery implemen-
ted standardized long-term prophylaxis for all transplanted
patients (Initially 1 × 200 mg, followed by 2 × 200 mg itra-
conazole daily). Hence, pharmacological reports did not
add to detection of further cases of IA. Only cases found
in pharmacological alerts were evaluated by our infection
control team. Not a single case of proven, probable or pos-
sible IA could be confirmed. All the cases detected were
positive for at least one of the other alerts.
Discussion
Surveillance of IA is important because it is the only
way minor trends and major changes in incidence
Table 2 Incidence densities of IA
Year # of cases
(proven and probable)
# of patient days incidence density
(per 100,000 patient days)
95% CI p-value
(vs. 2003)
2003 32 391.445 24 5.59; 11.54 -
2004 16 407.007 15 2.25; 6.38 0.008
2005 15 407.644 6 2.06; 6.07 0.427
2006 7 415.980 5 0.68; 3.47 0.044
2007 11 431.954 4 1.27; 4.56 0.804
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help identify IA cases in patients with various coexisting
organ diseases (which can make diagnosis difficult).
Thus, the CDC and several other experts in the field of
IA prevention recommend surveillance. Unfortunately,
however, so far, there is no standardized epidemiological
method available to do so.
In this investigation, we used a simplified surveillance
alert system that relied on three indicators to detect
possible cases of IA. This process allowed to screen for
IA in the entire hospital (not only in hematology) and
to detect possible clusters of cases especially in other
disciplines. Our data show that IA may occur in all
types of medical departments, and in all kinds of
patients with severe underlying diseases.
Our surveillance system was implemented in 2003 and
ended in 2007, which is why we did not apply the
revised EORTC criteria published later in 2008. Applica-
tion of the revised criteria in future studies covering a
different set of patients (e.g. patients with solid organ
transplantations, hereditary immunodeficiencies and
connective diseases) should by all means be considered,
bearing in mind, however, that the category of proven
invasive fungal disease can now apply to any patient,
regardless of whether the patient is immunocompro-
mised, whereas probable and possible categories are pro-
posed for immunocompromised patients only. Because
we would wish to include all patients the revised
EORTC criteria might [12] not be helpful. Definition of
nosocomial IA remains difficult. A better understanding
of early events related to IA onset will help improve
treatment of this disease, for which the prognosis
remains negative. Thus, in the study presented here,
infections were defined as early if occurring within 100
days of transplantation and as late if detected later than
100 days. To our knowledge, a clear definition of noso-
comial infection can only be given if there is at least
one negative respiratory culture after admission [7].
Cases with an infection occurring within seven days
after admission without a negative culture prior to a
positive result still remain uncertain and were thus
defined as possibly nosocomial
The majority of patients with IA had a history of trans-
plantation (visceral, cardiac, and thoracic surgery) (94;
44%). Only 72 (34%) of the IA cases were cared for in
Table 3 Underlying diseases for all confirmed cases of
invasive aspergillosis
underlying diseases proven +
probable
n=8 1
possible
n = 133
total (%)
n = 214
hematological diseases 17 (38%) 55 (41%) 72 (34%)
organ transplantation 39 (49%) 55 (41%) 94 (44%)
single lung transplantation 1 2 3
double lung transplantation 13 23 36
liver transplantation 9 12 21
heart transplantation 4 2 6
heart-lung transplantation 3 3 6
renal transplantation 4 0 4
stem cell transplantation 4 13 17
pancreas transplantation 1 0 1
liver diseases 12 14 26
lung diseases 15 31 4
kidney diseases 4 4 8
heart diseases 4 1 5
heart and lung diseases 3 5 10
pancreas diseases 1 0 1
malignancy (solid tumor) 10 (22%) 6 (5%) 15 (7%)
human immunodeficiency virus 0 0 0
immunosuppressive treatment 73
(85%)
117
(88%)
190
(89%)
Table 4 Underlying diseases for proven and probable
cases of invasive aspergillosis (IA) without
transplantation or primary immunosuppression
underlying diseases/therapy proven +
probable IA
n=8 1
total
(all proven
and probable
cases) (%)
tumor diseases 10 12.3%
colorectal cancer (colectomy, rectal
resection)
4 4.9%
gastric cancer (gastrectomy) 2 2.5%
cholangiocarcinoma (tumor
resection)
1 1.2%
hepatocellular carcinoma 2 2.5%
renal carcinoma (nephrectomy) 1 1.2%
other diseases 26 32.5%
gastroenterologic diseases 10 12.3%
necrotizing enterocolitis 1 1.2%
necrotizing pancreatitis 2 2.5%
chronical hepatitis B infection 3 3.7%
liver cirrhosis 3 3.7%
citrullinaemia 1 1.2%
prematurity 1 1.2%
heart diseases 4 4.9%
congenital heart disease 1 1.2%
dilatative cardiomyopathy 2 2.5%
endocarditis 1 1.2%
vascular diseases 1 1.2%
type B dissection (stent
implantation)
1 1.2%
renal diseases 4 6.2%
renal insufficiency 4 4.9%
other diseases 5 6.2%
multiple trauma 3 3.7%
sinusitis maxillaris 2 2.5%
Graf et al. BMC Infectious Diseases 2011, 11:163
http://www.biomedcentral.com/1471-2334/11/163
Page 5 of 9hematology or in infectious diseases units. This unex-
pected distribution has been reported previously [13]. Our
findings therefore implicate that IA surveillance needs to
be extended and should comprise the entire hospital
including all high risk units [9]. Accordingly, alert systems
that might already be in place for hematological patients
should be expanded to patients after organ transplantation
and patients with other severe chronic diseases.
Compared with the literature, we noticed a significant
decrease in the incidence density of IA and low rates
from 2005 through 2007 [13], which probably reflects
changes in antimycotic prophylaxis policy. During 2003
and 2004, antimycotic prophylaxis was implemented in
several high risk units. For example, the departments of
hemato-oncology and the cardio-thoracic surgery imple-
mented a standardized prophylaxis protocol for trans-
planted patients, which led to a significant decrease in
the number of cases.
Pharmacological reports did not lead to detection of
additional cases of IA. Not a single case of proven, prob-
able or possible IA could be confirmed by means of this
indicator alone. All the cases detected were positive for
at least one of the other indicators. However, we sug-
gested maintaining the indicator for surveillance pur-
poses because it was an important point of discussion
between clinicians and infection control team. During
prospective surveillance, this indicator was helpful in
encouraging clinicians intensify microbiological diagnos-
tics, which was essential for categorization of IA.
In terms of case investigation, it is important to empha-
size that chart review and audits with clinical personnel is
crucial for all potential cases presenting with symptoms
matching one of the indicators we were using. Other
authors who also use an active surveillance system report
that although computer-assisted surveillance may be
quite sensitive, it is not very specific [14]. This is why we
established the method of surveillance presented here.
However, extensive chart review is only necessary if
patients present a positive indicator. This way, we had
the possibility to quickly screen 234,095 patients
admitted during 2003 through 2007, but only 704 of that
number required a more detailed review. There are other
simplified surveillance methods in place, but they showed
to be suitable for special patient groups only, while
further clarification often remains impossible due to the
lack of additional clinical data [14].
Reliance on microbiological data alone to identify
cases may lead to ascertainment bias, because many
cases of IA are diagnosed radiographically, by pathologic
investigation or by clinical suspicion. Our method,
which includes three indicators that are as far as possi-
b l es t a n d a r d i z e d ,m a ya l s ob es u i t a b l ef o ru s ei no t h e r
institutions, and might even facilitate inter-institutional
comparison of incidence rates in special patient groups
or in all patients.
The EORTC criteria used in our study represent the
first established international criteria for definition of
IA. They were primarily developed for immunocompro-
mised patients with cancer and hematologic stem cell
transplantation; however, as shown here, they are also
applicable to other patient groups. Nevertheless, caution
should be exercised in applying the criteria. Only 56
(26%) of the 214 cases of IA investigated were proven,
25 (12%) were probable, whereas, according to these cri-
teria, the majority (133; 62%) were possible cases. With
regard to the possible cases, the true diagnosis remains
to some extent uncertain. Clinical diagnosis, microbiolo-
gical findings and the pathologic results may differ. If
certain data - especially microbiological and pathologic
results - are missing, the correct diagnosis can also
easily be missed. It is an important fact that the number
of respiratory samples taken may also influence the
Table 5 Classification of invasive aspergillosis by positive microbiological culture
positive microbiological samples/ alerts proven
n=5 6
probable
n=2 5
possible
n = 133
total
n = 214 (%)
microbiological culture 41 17 49 107 (50%)
broncho alveolar lavage 20 14 27 61 (29%)
bronchial secretion 13 7 26 46 (21%)
tracheal secretion 14 9 26 40 (19%)
0,00
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10,00
15,00
20,00
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Amphotericin B
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Figure 3 Usage of antifungal therapy calculated per 1000
Patient days.
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lance study because we included the whole hospital over
a long time, and different culturing regimes (e.g. routine
culturing of tracheal secretions or screening at admis-
sion in some ICUs) were used in various departments at
our facility.
For inter-institutional comparison of incidences it is
important to calculate the rates of possible and probable
nosocomial cases. In this study, 32 of the proven cases
(57%) had positive pathology results, 16 (29%) were
detected in autopsy and seven cases did not match any
other alerts, meaning that 13% of all proven cases would
not have been detected without autopsy. From 2003
through 2007, autopsy rates at our hospital ranged
between 14.1% and 20.9%, and decreased during the
investigation period. Thus, we surmise that some cases
were missed because of lacking autopsy. In Germany,
autopsy rates have decreased steadily since 1980 and are
the lowest in the world today [15]. Thus, studies carried
out under these circumstances may underestimate the
actual problem.
We documented antifungal therapy such as amphoter-
icin B, voriconazole and caspofungin. In our study,
reports from the in-house pharmacy did not help detect
diseased patients. However, they can help identify risk
patients. On the one hand, many patients received anti-
fungal treatment although we found that the criteria
were uncertain for IA. On the other hand, antifungal
drugs are used for prophylaxis, especially in transplanted
patients [4]. Obviously clinicians are often uncertain
about the indication for antimycotic therapy or aim to
prevent colonization in the first place [16]. IA is often
seen in patients with different severe chronic organ dis-
eases, making it difficult to get the diagnosis right with-
out hard microbiological and/or pathological data. Even
under adequate antifungal therapy, mortality rates of
between 30% and 80% are reported for IA, and antifun-
gal drugs might be used for prophylaxis more often
than for therapy [17]. It is worth noting that pharmaco-
logical data may be supportive for detection of IA cases,
although they are of little help for direct detection. Dur-
ing prospective surveillance these data may serve as a
first step for contacting clinicians, and for discussing
diagnostic procedures, infection control measures and
treatment options. Patients undergoing immunosuppres-
sive therapy have often been reported to be “high risk”
patients for acquiring IA, and especially patients suffer-
ing from hematological diseases and/or with stem cell
transplantation [18,19]. We are able to confirm these
findings since we also found a large number of IA in
transplanted patients, but also in patients with solid
organ malignancy tumors. Two patients were under-
going chemotherapy and three other patients were
receiving high dose steroidal therapy. Due to the rather
small number of patients we cannot define the presence
of a solid tumor as an independent risk factor; however,
we do recommend that patients with malignancies
should be included in a surveillance programme. In our
study, the incidence of likely nosocomial IA (proven and
probable cases) was 1.85% in organ transplanted patients
and 0.97% in stem cell transplanted patients. In other
studies, the incidence of IA was evaluated as a frequency
of 1 to 28% for patients with allogenous bone marrow
transplant graft [14,19]. IA incidence rates for solid
organ transplant patients varied depending on the type
of transplanted organ: 2 to 18% for lung [20-22], 1.5 to
10% for liver [23,24] and 1.3 to 7% for heart [25-27].
The concentration of Aspergillus spores in the sur-
rounding air may also influence the likelihood of subse-
quent infection. Fortunately, during the 60 months of
epidemiological surveillance, no outbreaks or clusters
and no association between the onset of IA and seasons
was observed.
In our study, crude mortality (45%) for proven and
probable IA cases was relatively low compared with the
findings of others (50-100%) [2,26,27]. Since patients
with IA often suffer from severe underlying diseases, we
cannot say with full certainty whether IA was causative
for or at least contributed to their fatal outcome. Thus,
t h er o l eo fI As o m e t i m e sr e m a i n su n k n o w n .S o m e
patients may be colonized with Aspergillus spp. for a
long time before developing terminal IA. In this case, IA
may rather serve as a sign of the severity of immuno-
suppression due to some other illness. In our study (34
deceased patients), the time frame from IA diagnosis to
death was only eight days in median, however, culturing
of the micro-organism may take several days. Thus, clin-
icians may not have enough time to choose and intro-
duce the appropriate treatment.
Our data show that surveillance of IA should be
implemented in all areas of the hospital that care for
severely ill patients. A multidisciplinary working group
of infection control staff, microbiologists, pharmacolo-
gists and clinicians would give a straightforward
approach to IA surveillance and help clinicians detect
all kinds of high risk patients and cases of IA more
easily and at an earlier stage. Our five year survey shows
a high frequency of IA cases in patients hospitalized in
units other than hematology. Thus, our study empha-
sizes the importance of IA surveillance, not just in
hematology units; rather, surveillance should be
expanded to cover all high-risk units (ICUs, respiratory
care, infectious diseases and internal medicine units, in
particularly).
Conclusions
This study provides an overview on the incidence of IA
cases in a university hospital through use of a
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findings on patient groups, prophylaxis and treatment
options and provides new insights into certain aspects
of IA surveillance covering the entire hospital.
Only the charts of 704 of 234,095 patients admitted
( 0 . 0 0 3 % )o v e raf i v ey e a rt i m ef r a m e( 2 0 0 3t o2 0 0 7 )
required more intensive reviewing as those patients had
at least one special indicator (microbiology, pathology,
pharmacology). Yet, diagnosis remains difficult because
13% of the cases were diagnosed by autopsy only.
One should keep in mind that so-called “high risk”
patients for IA are not only those undergoing trans-
plantation, but all other patients receiving immunosup-
pressive therapy. Thus, this type of surveillance
approach should be performed hospital-wide and
should include all patients that are potentially at
increased risk of IA.
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